Study results concerning remdesivir benefits in COVID-19
Remdesivir is the only drug other than dexamethasone shown to benefit those infected with COVID-19 in a large, randomized trial. It shortened the amount of time patients needed to spend in the hospital, but it did not have a statistically significant benefit in preventing deaths. It is the only drug that has gained emergency use authorization from the US FDA.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Early randomized trials are unable to provide evidence for reducing time to clinical improvement, clearance of virus, or mortality amongst those given Remdesivir as COVID-19 intervention
Adverse health effects amongst those given Remdesivir as COVID-19 intervention
Availability of remdesivir
Clinical trials of Remdesivir around the world
Intracellular processing of Remdesivir
Global Production of Remdesivir
Learn After
Related
Early randomized trials are unable to provide evidence for reducing time to clinical improvement, clearance of virus, or mortality amongst those given Remdesivir as COVID-19 intervention
Adverse health effects amongst those given Remdesivir as COVID-19 intervention
Availability of remdesivir
Clinical trials of Remdesivir around the world
Intracellular processing of Remdesivir
Global Production of Remdesivir